Evidence map›Paper›PMID 22689099›Full record

ArticleCellular and molecular life sciences : CMLS2012

Development of transcriptomic biomarker signature in human saliva to detect lung cancer.

Lei Zhang, Hua Xiao, Hui Zhou, Silverio Santiago, Jay M Lee, Edward B Garon, Jieping Yang, Ole Brinkmann, Xinmin Yan, David Akin and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. BreathERJ open research · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Circulating biomarkers for diagnosis and response to therapies in cancer patients.International review of cell and molecular biology · 2025
    Review
  12. Unveiling the oncogenic role of LZTS1 in colorectal cancer.Journal of cellular and molecular medicine · 2024
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. [Latest Findings on Salivary Tumor Biomarkers].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2023
    Review
  18. Article
  19. Saliva Diagnostics.Annual review of analytical chemistry (Palo Alto, Calif.) · 2022
    Review
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lei Zhang *School of Dentistry and Dental Research Institute, University of California, 10833 Le Conte Avenue, 73-024 CHS, Los Angeles, CA 90095, USA.
Hua Xiao *School of Dentistry and Dental Research Institute, University of California, 10833 Le Conte Avenue, 73-024 CHS, Los Angeles, CA 90095, USA.
Hui ZhouSchool of Dentistry and Dental Research Institute, University of California, 10833 Le Conte Avenue, 73-024 CHS, Los Angeles, CA 90095, USA.
Silverio SantiagoDavid Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA 90095, USA.
Jay M LeeJonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA 90095, USA.
Edward B GaronDepartment of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA 90095, USA.
Jieping YangSchool of Dentistry and Dental Research Institute, University of California, 10833 Le Conte Avenue, 73-024 CHS, Los Angeles, CA 90095, USA.
Ole BrinkmannSchool of Dentistry and Dental Research Institute, University of California, 10833 Le Conte Avenue, 73-024 CHS, Los Angeles, CA 90095, USA.
Xinmin YanSchool of Dentistry and Dental Research Institute, University of California, 10833 Le Conte Avenue, 73-024 CHS, Los Angeles, CA 90095, USA.
David AkinSchool of Dentistry and Dental Research Institute, University of California, 10833 Le Conte Avenue, 73-024 CHS, Los Angeles, CA 90095, USA.
David ChiaDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA 90095, USA.
David ElashoffDepartment of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA 90095, USA.
No-Hee ParkSchool of Dentistry and Dental Research Institute, University of California, 10833 Le Conte Avenue, 73-024 CHS, Los Angeles, CA 90095, USA.
David T W WongSchool of Dentistry and Dental Research Institute, University of California, 10833 Le Conte Avenue, 73-024 CHS, Los Angeles, CA 90095, USA.

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
The Early Detection Research Network Biomarker Resource Laboratory at UCLAU24CA086366 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIA, DAVID S. · 2000 to 2014
$7.3M
Inhibiting EGFR and ER pathways in NSCLCK23CA149079 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GARON, EDWARD B · 2011 to 2015
$826k
NCATS NIH HHS UL1 TR000124NCI NIH HHS K23 CA149079NCI NIH HHS U24 CA086366
6 · The paper itself

Abstract

Lung cancer is the leading cause of cancer death for both men and women worldwide. Since most of the symptoms found for lung cancer are nonspecific, diagnosis is mostly done at late and progressed stage with the consecutive poor therapy outcome. Effective early detection techniques are sorely needed. The emerging field of salivary diagnostics could provide scientifically credible, easy-to-use, non-invasive and cost-effective detection methods. Recent advances have allowed us to develop discriminatory salivary biomarkers for a variety of diseases from oral to systematic diseases. In this study, salivary transcriptomes of lung cancer patients were profiled and led to the discovery and pre-validation of seven highly discriminatory transcriptomic salivary biomarkers (BRAF, CCNI, EGRF, FGF19, FRS2, GREB1, and LZTS1). The logistic regression model combining five of the mRNA biomarkers (CCNI, EGFR, FGF19, FRS2, and GREB1) could differentiate lung cancer patients from normal control subjects, yielding AUC value of 0.925 with 93.75 % sensitivity and 82.81 % specificity in the pre-validation sample set. These salivary mRNA biomarkers possess the discriminatory power for the detection of lung cancer. This report provides the proof of concept of salivary biomarkers for the non-invasive detection of the systematic disease. These results poised the salivary biomarkers for the initiation of a multi-center validation in a definitive clinical context.

Indexed as

Adaptor Proteins, Signal TransducingAgedBiomarkers, TumorCase-Control StudiesCysteine-Rich Protein 61DNA-Binding ProteinsFemaleFibroblast Growth FactorsHumansLung NeoplasmsMaleMembrane ProteinsMiddle AgedNeoplasm ProteinsPredictive Value of TestsProto-Oncogene Proteins B-rafAdaptor Proteins, Signal TransducingBiomarkers, TumorBRAF protein, humanCCN1 protein, humanCysteine-Rich Protein 61DNA-Binding ProteinsFGF19 protein, humanFibroblast Growth FactorsFRS2 protein, humanGREB1 protein, humanLZTS1 protein, humanMembrane ProteinsNeoplasm ProteinsProto-Oncogene Proteins B-rafTumor Suppressor Proteins

Identifiers

PMID22689099
PMCPMC4121486

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.